skip to main content

Tolvaptan ALT Monitoring Protocol — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModeratePolycystic Kidney DiseaseTolvaptan ALT Monitoring ProtocolESENeph

A 35-year-old woman with polycystic kidney disease on Tolvaptan has her liver function monitored monthly. At month 8, her ALT is 2x upper limit of normal (previously normal). She is asymptomatic. What is the recommended action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Repeat LFTs in 1-2 weeks; if ALT rises to >3x ULN or bilirubin rises, stop Tolvaptan immediately; at 2x ULN, closer monitoring with more frequent LFTs is warranted

Tolvaptan hepatotoxicity monitoring follows a structured protocol per NICE TA877 and the SPC: monthly LFTs for the first 18 months, then 3-monthly. At 2x ULN ALT (without bilirubin rise), the recommendation is to increase monitoring frequency (repeat in 1-2 weeks) while continuing Tolvaptan cautiously. If ALT rises to >3x ULN, or if total bilirubin rises to >2x ULN, or if ALT >3x ULN with bilirubin >2x ULN (Hy's Law – high risk of drug-induced liver failure), Tolvaptan must be stopped immediately and not rechallenged.

Reference: NICE TA877 2022; Tolvaptan (Jynarque) SPC; Hy's Law – FDA Guidance